Thorac Cancer: Efficacy of carboplatin + albumin-paclitaxel combination in the treatment of recurrent small cell lung cancer (SCLC)

Recently, Thoracic Cancer published the results of a phase II clinical study, mainly to evaluate the efficacy and safety of nab-paclitaxel combined with carboplatin after the progression of standard chemotherapy for small cell lung cancer (SCLC)
.

Recently, Thoracic Cancer published the results of a phase II clinical study, mainly to evaluate the efficacy and safety of nab-paclitaxel combined with carboplatin after the progression of standard chemotherapy for small cell lung cancer (SCLC)
.

Mainly to evaluate the efficacy and safety of nab-paclitaxel combined with carboplatin after the progression of standard chemotherapy for small cell lung cancer (SCLC)

Enrolled patients received nab-paclitaxel (100 mg/m2, d1, d8, and d15), and carboplatin (AUC=5, d1) every 3 weeks until disease progression or unacceptable toxicity
.

The primary endpoint was objective response rate

Enrolled patients received nab-paclitaxel (100 mg/m2, d1, d8, and d15), and carboplatin (AUC=5, d1) every 3 weeks until disease progression or unacceptable toxicity

A total of 21 patients were included in the study, all of whom were eligible for inclusion in the analysis
.

The median age was 70 years (range: 54 to 85), 18 patients were male (85.

A total of 21 patients were included in the study, all of whom were eligible for inclusion in the analysis

Partial responses were achieved in 4 patients and stable disease in 6 patients, with an overall response rate of 19.

The median progression-free survival was 2.
5 months (95% CI: 1.
5-3.
4 months), and the median survival time was 5.
1 months (95% CI: 2.
1-8.
1 months)
.

The median progression-free survival was 2.
5 months (95% CI: 1.
5-3.
4 months), and the median survival time was 5.
1 months (95% CI: 2.
1-8.
1 months)
.

The median progression-free survival was 2.

Eighteen (85.
7%) patients experienced grade 3 or 4 hematological toxicity
.

11 cases (52.

Eighteen (85.

In conclusion, the study showed that the combination of carboplatin + albumin-paclitaxel has certain efficacy in the treatment of recurrent SCLC, although the primary endpoint was not met
.

In conclusion, the study showed that the combination of carboplatin + albumin-paclitaxel has certain efficacy in the treatment of recurrent SCLC, although the primary endpoint was not met
.

Studies have shown that the combination of carboplatin + albumin-paclitaxel has some efficacy in the treatment of recurrent SCLC, although the primary endpoint was not met

Original source:

Original source:

Naoya Ikeda, Ryo Arai, Sayo Soda, et al.
Carboplatin plus nab-paclitaxel for recurrent small cell lung cancer: A phase II study.
Thorac Cancer.
2022;1–7.
DOI: 10.
1111/1759-7714.
14394.

Naoya Ikeda, Ryo Arai, Sayo Soda, et al.
Carboplatin plus nab-paclitaxel for recurrent small cell lung cancer: A phase II study.
Thorac Cancer.
2022;1–7.
DOI: 10.
1111/1759-7714.
14394.

 

leave a message here